We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Horizon Pharma (HZNP) Q1 Earnings & Sales Miss, Shares Fall
Read MoreHide Full Article
Horizon Pharma plc reported lower-than-expected results for the first quarter of 2018. Following the news, the company’s shares went down 5.6%. Horizon Pharma’s stock has declined 5.4% year to date compared with the industry’s fall of 12.3%.
The company reported first-quarter adjusted earnings of 3 cents per share, which missed the Zacks Consensus Estimate of 11 cents and were much lower than 21 cents reported in the year-ago quarter.
Sales in the first quarter were up 1.4% year over year to $223.9 million but missed the Zacks Consensus Estimate of $239.45 million.
Quarter in Detail
The Orphan unit recorded revenues of $114.7 million, up 2% from the year-ago period. Growth in net sales of Ravicti, which generated $49.1 million in the quarter, up 12% year over year, was partially offset by lower sales of Actimmune, Buphenyl and Quinsair.
Additionally, Procysbi contributed to the performance with net sales of $34.9 million, up 2% year over year. Actimmune sales in the reported quarter were $24.9 million, down 5% year over year.
Procysbi’s lower sales growth and Quinsair declining sales was due to divesting of marketing rights in Europe, the Middle East and Africa (“EMEA”) regions
The Rheumatology unit generated $57.5 million from sales, up 35% year over year. Also, Krystexxa sales in the quarter were strong and came in at $46.7 million, up 48% year over year, driven by a strong and continued year-over-year vial demand.
Primary Care garnered revenues of $51.7 million, down 21% year over year. The decline in net sales was due to greater-than-anticipated seasonality impact and accrual of inventory in sales channel.
In the reported quarter, net sales of Pennsaid2%, Duexix and Vimovo were $26.8 million, $15.7 million and $8.4 million, respectively.
Adjusted research and development (R&D) expenses were up 40.3% to $15.2 million while adjusted selling, general and administrative expense was $146.1 million, up 10.4% year over year.
2018 Guidance Increased
Horizon Pharma raised its outlook for 2018. It now expects sales in the range of $1.17-$1.2 billion (previously $1.15-$1.18 billion), mainly driven by expected strong growth in its orphan and rheumatology business units, especially Krystexxa.
The company expects Krystexxa sales to increase 65% year over year in 2018 due to a one-year delay in implementation of the U.S. Government's Health Resource and Services Administration's Final Rule on 340B drug ceiling price to Jul 1, 2019.
Other Updates
In February 2018, the company filed a supplemental New Drug Application to expand the age range in the label of Raviciti from two months of age and older to birth and older.
In January 2018, the company announced two programs for developing next-generation biologics – HZN-003 and PASylated uricase technology – for the treatment of uncontrolled gout.
Currently, Horizon Pharma is evaluating KRYSTEXXA in combination with commonly used two different immunomodulators in two investigator-initiated studies – RECIPE and TRIPLE – for enhancing the response rate of the drug in gout patients.
The company is progressing well with the phase III study for the evaluation of teprotumumab in moderate-to-severe active thyroid eye disease. The company expects to complete enrollment in the study by the end of 2018.
Meanwhile, the company is working on expanding Actimmune’s label. An investigator-initiated study at the Moffitt Cancer Center is underway and enrolling patients. The study is evaluating Actimmune in combination with Roche Holdings’ (RHHBY - Free Report) Herceptin, Perjeta and Taxol in certain advanced breast cancer patients. A phase I study will evaluate Actimmune in combination with Bristol-Myers Squibb Company’s (BMY - Free Report) Opdivo in kidney and bladder cancer. Actimmune is also being evaluated in combination with Merck & Co’s (MRK - Free Report) Keytruda to treat cutaneous t-cell lymphoma patients in a phase II study.
New Operating Structure
In line with Horizon Pharma’s long-term strategy, management announced that beginning second quarter, it will report its results under two operating segments. The company will separate its strategic growth business, orphan and rheumatology, from the primary care business.
The company expects the new structure to help it in better allocation of resources in developing products for unmet treatment needs of patients with rare diseases.
Our Take
Horizon Pharma’s first-quarter results were not impressive as the company missed both the top- and bottom-line estimates. However, the sales guidance for 2018 was encouraging. We expect Krystexxa, Ravicti and Actimmune to drive further growth.
Although the company’s focus on developing Krystexxa and Actimmune is beneficial for its future, we expect the studies to increase operating expenses.
Horizon Pharma Public Limited Company Price, Consensus and EPS Surprise
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Horizon Pharma (HZNP) Q1 Earnings & Sales Miss, Shares Fall
Horizon Pharma plc reported lower-than-expected results for the first quarter of 2018. Following the news, the company’s shares went down 5.6%. Horizon Pharma’s stock has declined 5.4% year to date compared with the industry’s fall of 12.3%.
The company reported first-quarter adjusted earnings of 3 cents per share, which missed the Zacks Consensus Estimate of 11 cents and were much lower than 21 cents reported in the year-ago quarter.
Sales in the first quarter were up 1.4% year over year to $223.9 million but missed the Zacks Consensus Estimate of $239.45 million.
Quarter in Detail
The Orphan unit recorded revenues of $114.7 million, up 2% from the year-ago period. Growth in net sales of Ravicti, which generated $49.1 million in the quarter, up 12% year over year, was partially offset by lower sales of Actimmune, Buphenyl and Quinsair.
Additionally, Procysbi contributed to the performance with net sales of $34.9 million, up 2% year over year. Actimmune sales in the reported quarter were $24.9 million, down 5% year over year.
Procysbi’s lower sales growth and Quinsair declining sales was due to divesting of marketing rights in Europe, the Middle East and Africa (“EMEA”) regions
The Rheumatology unit generated $57.5 million from sales, up 35% year over year. Also, Krystexxa sales in the quarter were strong and came in at $46.7 million, up 48% year over year, driven by a strong and continued year-over-year vial demand.
Primary Care garnered revenues of $51.7 million, down 21% year over year. The decline in net sales was due to greater-than-anticipated seasonality impact and accrual of inventory in sales channel.
In the reported quarter, net sales of Pennsaid2%, Duexix and Vimovo were $26.8 million, $15.7 million and $8.4 million, respectively.
Adjusted research and development (R&D) expenses were up 40.3% to $15.2 million while adjusted selling, general and administrative expense was $146.1 million, up 10.4% year over year.
2018 Guidance Increased
Horizon Pharma raised its outlook for 2018. It now expects sales in the range of $1.17-$1.2 billion (previously $1.15-$1.18 billion), mainly driven by expected strong growth in its orphan and rheumatology business units, especially Krystexxa.
The company expects Krystexxa sales to increase 65% year over year in 2018 due to a one-year delay in implementation of the U.S. Government's Health Resource and Services Administration's Final Rule on 340B drug ceiling price to Jul 1, 2019.
Other Updates
In February 2018, the company filed a supplemental New Drug Application to expand the age range in the label of Raviciti from two months of age and older to birth and older.
In January 2018, the company announced two programs for developing next-generation biologics – HZN-003 and PASylated uricase technology – for the treatment of uncontrolled gout.
Currently, Horizon Pharma is evaluating KRYSTEXXA in combination with commonly used two different immunomodulators in two investigator-initiated studies – RECIPE and TRIPLE – for enhancing the response rate of the drug in gout patients.
The company is progressing well with the phase III study for the evaluation of teprotumumab in moderate-to-severe active thyroid eye disease. The company expects to complete enrollment in the study by the end of 2018.
Meanwhile, the company is working on expanding Actimmune’s label. An investigator-initiated study at the Moffitt Cancer Center is underway and enrolling patients. The study is evaluating Actimmune in combination with Roche Holdings’ (RHHBY - Free Report) Herceptin, Perjeta and Taxol in certain advanced breast cancer patients. A phase I study will evaluate Actimmune in combination with Bristol-Myers Squibb Company’s (BMY - Free Report) Opdivo in kidney and bladder cancer. Actimmune is also being evaluated in combination with Merck & Co’s (MRK - Free Report) Keytruda to treat cutaneous t-cell lymphoma patients in a phase II study.
New Operating Structure
In line with Horizon Pharma’s long-term strategy, management announced that beginning second quarter, it will report its results under two operating segments. The company will separate its strategic growth business, orphan and rheumatology, from the primary care business.
The company expects the new structure to help it in better allocation of resources in developing products for unmet treatment needs of patients with rare diseases.
Our Take
Horizon Pharma’s first-quarter results were not impressive as the company missed both the top- and bottom-line estimates. However, the sales guidance for 2018 was encouraging. We expect Krystexxa, Ravicti and Actimmune to drive further growth.
Although the company’s focus on developing Krystexxa and Actimmune is beneficial for its future, we expect the studies to increase operating expenses.
Horizon Pharma Public Limited Company Price, Consensus and EPS Surprise
Horizon Pharma Public Limited Company Price, Consensus and EPS Surprise | Horizon Pharma Public Limited Company Quote
Zacks Rank
Horizon Pharma currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>